The present invention relates to a compound of the general formula (III) or a salt, solvate or prodrug thereof, as well as medical uses involving them, wherein (III) A1 is selected from the group consisting of N and C-R8； A2 is selected from the group consisting of N and C-R3； A3 is selected from the group consisting of N and C-R9； A4 and A5 and A6 are independently selected from the group consisting of N and C-R1； R1 is selected from the group consisting of hydrogen, (C1-C3)alkyl, halogen, (C1-C3)alkoxy and (C1-C3)haloalkyl； R2 is selected from the group consisting of hydrogen, halogen and (C1-C3)alkyl； R3 is selected from the group consisting of hydrogen, (C1-C3)alkyl, NR4R5, (C1-C3)alkyl- NR4R5 and cyano； wherein R4 and R5 are independently selected from the group consisting of hydrogen, (C3- C5)cycloalkyl, (C3-C5)heterocycloalkyl, (C1-C3)alkyl, or R4 and R5 together with the nitrogen atom to which they are attached form a 5- to 7-membered heterocyclic ring optionally comprising in addition to the aforementioned nitrogen atom a further heteroatom group selected from the group consisting of O and NR6, wherein R6 is selected from the group consisting of hydrogen, methyl, acetyl and formyl； Y is selected from the group consisting of O and S； R7 is selected from the group consisting of hydrogen, and (C1-C3)alkyl； R8 is selected from the group consisting of (C1-C4)alkyl, (C3-C5)cycloalkyl, and (C3- C5)heterocycloalkyl； R9 is selected from the group consisting of hydrogen, (C1-C3)alkyl, (C1-C3)alkoxy, and methods for producing such compounds.La présente invention concerne un composé de la formule générale (III) ou son sel, solvate ou promédicament, ainsi que des utilisations médicales les concernant, où (III) A1 est sélectionné dans le groupe constitué de N et C-R8 ； A2 est sélectionné dans le groupe constitué de N et C-R3 ； A3 est sélectionné dans le groupe constitué de N et C-R9 ； A4 et A5 et A6 sont indépendamment sélectionnés dans le groupe constitué de N et C-R1
